Gregory Berk, M.D., the Company s President of R&D and Chief Medical Officer noted, "This pre-clinical evidence suggests, despite the difference in circulating immune cells of Stage IVB NSCLC patients, a mesothelin-targeted TriKE can work alongside current standard of care and provide benefit even in the hypoxic environment of a solid
Download as PDF February 17, 2022 7:05am EST Event will feature Michael Kalos, Ph.D., member of IMV’s Board of Directors and internationally recognized expert in T cell therapy and immunotherapy.
Ghassan Abou-Alfa, MD , and colleagues, found that a combination of the immunotherapy drugs durvalumab (IMFINZI ® ) plus the experimental drug tremelimumab significantly improved overall survival in people with unresectable hepatocellular cancer , compared with people who received sorafenib (NEXAVAR ® ), a current standard of care. Dr.